TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01887080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: This group had the exercise program, thrice a week for eight weeks.~The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.~The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent
Description: This group had the exercise program after electrolipolysis, thrice a week for eight weeks.~The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).~Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings.

Intervention type: OTHER
Group type: OTHER
Intervention: Cardiovascular Risk Factors
Description: It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Factors
Description: It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiovascular Risk Factors
Description: It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
Study: NCT02329548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alizarin Red
Description: An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
Study: NCT01417429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg/a day or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Nicotine
Description: 1.0 mg/70 kg of nicotine against saline
Study: NCT03051971

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating Mesh Nebulizer
Description: short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer
Description: short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
Study: NCT02953938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)~0.5 mg ranibizumab applied one + PRN as intravitreal injection of 0.05 mL, with or without laser treatment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Grid&Direct short pulse laser photocoagulation
Description: Grid\&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
Study: NCT05191186

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grass pollen extract - Alutard Phleum pratense, ALK
Description: injection in lymph node
Study: NCT03592875

Intervention type: BEHAVIORAL
Intervention: Professional nurses
Description: The nurses will be interviewed by a semi-structured guiding with 16 questions addressing aspects related to Nursing Care Systematization knowledge and practices.
Study: NCT03350048

Intervention type: DIAGNOSTIC_TEST
Intervention: Trans-Dot point-of-care test
Description: Training set participants will be recruited and receive investigations for TB. Blood samples will also be collected from them for performance of ELISAs and laboratory-based TransDot tests. These blood samples will be drawn at baseline, week 8 and week 24 at end of treatment for confirmed TB cases and at baseline for non-TB cases.~Test set participants will be recruited and receive investigations for TB. A POC TransDot test will be performed on fingerprick blood at baseline, and at week 8 and week 24 in participants on TB treatment, as well as a laboratory based TransDot test on serum at baseline. The week 8 and week 24 TransDot tests will be used to investigate the test's utility as an indicator of treatment response.
Study: NCT01226277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0917
Description: Oral repeating dose
Study: NCT00617890

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: robatumumab
Description: Robatumumab IV every two weeks until disease progression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: robatumumab
Description: Robatumumab IV every two weeks until disease progression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: robatumumab
Description: Robatumumab IV every two weeks until disease progression.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: robatumumab
Description: Robatumumab IV every two weeks until disease progression.
Study: NCT02799667

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dressing
Description: Patients are randomized to the standard dressing at the time of fascial closure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy Dressing
Description: Patients are randomized to the NPWT at the time of fascial closure.
Study: NCT00996736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Natamycin
Description: 5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
Study: NCT03928587

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2 billion CFU in total of the two strains Lactobacillus paracasei subsp. paracasei and Lactobacillus rhamnosus and arginine.
Description: One lozenge once daily for 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 12 months
Study: NCT03129945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine
Description: Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
Study: NCT00996736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: 1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Study: NCT01843283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Enhancement Meaningful Activity (DEMA)
Study: NCT03129945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
Study: NCT00694473

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Navigator
Description: Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
Study: NCT04411511

Intervention type: OTHER
Intervention: Exposure to the Dutch measures due to the Covid-19 pandemic.
Description: Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.

Intervention type: OTHER
Intervention: Exposure to the Dutch measures due to the Covid-19 pandemic.
Description: Several measures are taken in The Netherlands, due to the Covid-19 virus and pandemic. For example, closure of schools and sportclubs, and advices to stay at home as much as possible. During the pandemic, several measures also will be scaled down.
Study: NCT04117620

Intervention type: OTHER
Intervention: Pediatric Vestibular Symptom Questionnaire
Description: Subjects respond to the translated questionnaire twice with 15 days interval

Intervention type: OTHER
Intervention: Pediatric Vestibular Symptom Questionnaire
Description: Subjects respond to the translated questionnaire twice with 15 days interval
Study: NCT01783028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker support
Description: For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
Study: NCT00599287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol
Description: Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
Study: NCT01680861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of \<4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric Coated Mycophenolate Sodium (EC-MPS)
Description: EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
Study: NCT03365154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardio Flow FreedomFlow™ Orbital Atherectomy System treatment
Description: Occlusive lesions will be treated using atherectomy with or without adjunctive low pressure balloon angioplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balloon Angioplasty
Description: Low pressure balloon angioplasty may be used following atherectomy
Study: NCT01680861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
Study: NCT05177276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study: NCT01843283

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support (IS)
Study: NCT03577236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring System consists of the Spring Delivery System with Implant, Spring Scope, Camera Control Unit (CCU), Measurement Tool, and Spring Retrieval Tool.
Study: NCT01729702

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample collection
Study: NCT00815451

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acticoa polyphenol-rich dark chocolate
Description: 20g to be distributed throughout the day for 4 weeks
Study: NCT03602690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Darunavir/ritonavir + optimized NRTI
Description: Dolutegravir 50mg once daily Darunavir/ritonavir 600/100 twice daily Optimized NRTI recycling with lamivudine and one other NRTI (zidovudine or tenofovir or abacavir)
Study: NCT05013671

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repositioning maneuvers
Description: The calcium crystals floating in the endolymphatic fluid will put back in place by putting the patient in several sitting and lying positions during specific repositioning maneuvers. During these maneuvers the calcium crystals will float from the semicircular canals back into the utriculus, after which the dizziness symptoms should disappear

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: balance
Description: compare the balance of residents with BPPV with residents without BPPV

Intervention type: OTHER
Group type: OTHER
Intervention: balance
Description: compare the balance of residents with BPPV with residents without BPPV
Study: NCT03482713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 45 mg
Description: Gefapixant 45 mg (film-coated tablet) to be administered orally BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (film-coated tablet) matching gefapixant to be administered orally BID
Study: NCT02768298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 100 mg bid for 2 weeks followed by LCZ696 200 mg bid for 10 weeks. Treatment was administered as oral tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: Enalapril 5 mg bid for 2 weeks followed by enalapril 10 mg bid for 10 weeks. Treatment was administered as oral tablets.~Patients who prior Screening were at a stable daily dose of enalapril above 10 mg per day (or corresponding doses of other ACEI/ARB) started the study at a dose of enalapril 10 mg bid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching enalapril
Description: Patients randomized to LCZ696 arm also received placebo matching enalapril (enalapril 0 mg tablets) to ensure the blinding during the entire course of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching LCZ696
Description: Patients randomized to enalapril arm also received placebo matching LCZ696 (LCZ696 0 mg tablets) to ensure the blinding during the entire course of the study.
Study: NCT04455659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-cutaneous Electrical Nerve Stimulation
Description: TENS that was applied once daily, three times per week for 8 weeks. Each treatment session was conducted for 20 minutes, two electrodes were positioned over the perineal area between anus and scrotum on the Centrum tendineum, while the other two electrodes were applied under the buttocks medially at the level of the ischial spines (medial to the ischial spines bilaterally) with the patient in comfortable supine hook-lying position with abducted hips. to prevent burn beneath the electrodes, the surface area of the electrode should be equal to or greater than 4 cm2 to minimize the heat production. In addition, to decrease the current density between electrodes, the inter-electrode distance was less than the cross sectional area of the electrode

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional physical therapy exercise
Description: physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy exercise
Description: physical therapy program for 30 minutes, and 3 times per week for 8 weeks in the form of strengthening exercise, clam - shell exercise, and stretching exercise focusing on obturator internus muscle, range of motion exercise for the hip and pelvis musculature for 30 minute three times a week for consecutive 8 weeks , each type of exercise was performed for a duration of 6 seconds and repeated 10 times
Study: NCT04524039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation using a MagPro X100
Description: Patients randomized to receive iTBS in left dorsolateral prefrontal cortex, each treatment will consist of 600 stimuli (triplet 50 Hz bursts, repeated at 5 Hz; 2 s on and 8 s off; total duration of 3 min 12 s). Simulated iTBS will be administered using Magventure static cooling MCF-B65 coil.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham intermittent theta burst stimulation using a MagPro X100
Description: Patients randomized to receive sham iTBS will undergo the same procedure to patients receiving real iTBS. Sham iTBS will be administered using Magventure static cooling MCF-P-B65 coil that shares the same mechanical outline and produces identical sound level to MCF-B65 coil without stimulating the cerebral cortex.
Study: NCT02130466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: oral capsule
Study: NCT05191186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grass pollen extract - Alutard Phleum pratense, ALK
Description: injection in lymph node
Study: NCT02366702

Intervention type: DEVICE
Intervention: Lower Limb Powered Knee-Ankle Prosthesis
Study: NCT01386411

Intervention type: GENETIC
Intervention: BRCA testing and questionnaire assessments
Description: If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.